We are live on ! Find out more
PHS

PFM Health Sciences Portfolio holdings

AUM $1.1B
1-Year Est. Return 57.92%
This Fund
S&P 500
This Quarter Est. Return
+0.34%
1 Year Est. Return
+57.92%
3 Year Est. Return
+183.93%
5 Year Est. Return
+283%
10 Year Est. Return
+2,507.28%
AUM
$2.02B
AUM Growth
-$106M
Cap. Flow
-$45.5M
Cap. Flow %
-2.25%
Top 10 Hldgs %
46.17%
Holding
96
New
10
Increased
23
Reduced
12
Closed
18

Top Buys

Rank Stock Value
1
UNH icon
UnitedHealth
UNH
+$24.5M
2
AMGN icon
Amgen
AMGN
+$23.8M
3
SYK icon
Stryker
SYK
+$20.1M
4
JNJ icon
Johnson & Johnson
JNJ
+$19.2M
5
BSX icon
Boston Scientific
BSX
+$12.8M

Top Sells

Rank Stock Value
1
LEGN icon
Legend Biotech
LEGN
+$41.2M
2
ZBH icon
Zimmer Biomet
ZBH
+$39.6M
3
AVTR icon
Avantor
AVTR
+$34.3M
4
VEEV icon
Veeva Systems
VEEV
+$27.5M
5
WST icon
West Pharmaceutical
WST
+$20.3M

Sector Composition

Rank Sector Weight
1 Healthcare 88.57%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
WAT icon
51
Waters Corp
WAT
$37B
$5.96M 0.29%
20,541
-17,923
-47% -$5.72M
XENE icon
52
Xenon Pharmaceuticals
XENE
$6.06B
$5.87M 0.29%
150,554
– –
CNTA
53
DELISTED
Centessa Pharmaceuticals
CNTA
$5.74M 0.28%
635,643
+320,969
+102% +$3.04M
DAWN
54
DELISTED
Day One Biopharmaceuticals
DAWN
$5.47M 0.27%
396,644
+41,393
+12% +$606K
MGX icon
55
Metagenomi Therapeutics
MGX
$44.8M
$5.17M 0.26%
1,267,002
– –
CGEM icon
56
Cullinan Oncology
CGEM
$1.01B
$5.16M 0.26%
296,036
+40,069
+16% +$853K
ALKS icon
57
Alkermes
ALKS
$8.22B
$4.94M 0.24%
205,073
-224,500
-52% -$5.51M
APLS
58
DELISTED
Apellis Pharmaceuticals
APLS
$3.18M 0.16%
82,952
– –
VKTX icon
59
Viking Therapeutics
VKTX
$3.7B
$3.12M 0.15%
58,811
+25,984
+79% +$1.7M
OM icon
60
Outset Medical
OM
$84.7M
$2.87M 0.14%
49,640
-28,229
-36% -$1.38M
IOBT
61
DELISTED
IO Biotech
IOBT
$2.74M 0.14%
2,341,107
– –
EYPT icon
62
EyePoint Inc
EYPT
$1.03B
$2.55M 0.13%
292,926
+122,055
+71% +$1.7M
TSBX
63
DELISTED
Turnstone Biologics
TSBX
$2.44M 0.12%
932,348
+11,372
+1% +$32.5K
GBIO
64
DELISTED
Generation Bio
GBIO
$2.22M 0.11%
78,791
-83,458
-51% -$2.71M
SGMT icon
65
Sagimet Biosciences
SGMT
$439M
$2.22M 0.11%
649,006
-153,706
-19% -$705K
PMVP icon
66
PMV Pharmaceuticals
PMVP
$59.2M
$2.07M 0.1%
1,275,462
– –
CLDX icon
67
Celldex Therapeutics
CLDX
$2.99B
$1.93M 0.1%
52,120
+17,120
+49% +$646K
INBX icon
68
Inhibrx
INBX
$1.2B
$1.92M 0.1%
+135,546
New +$2.12M
KROS icon
69
Keros Therapeutics
KROS
$199M
$1.52M 0.08%
+33,355
New +$1.79M
QURE icon
70
uniQure
QURE
$3.03B
$1.23M 0.06%
274,540
– –
IOVA icon
71
Iovance Biotherapeutics
IOVA
$1.82B
$1.23M 0.06%
152,795
-157,959
-51% -$1.69M
WAY
72
Waystar Holding Corp
WAY
$4.05B
$753K 0.04%
+35,000
New +$758K
TNYA icon
73
Tenaya Therapeutics
TNYA
$161M
$689K 0.03%
222,222
– –
SANA icon
74
Sana Biotechnology
SANA
$871M
$605K 0.03%
110,834
-564,166
-84% -$4.5M
BOLD
75
Boundless Bio
BOLD
$56.2M
$544K 0.03%
140,513
– –
1 2
3
4

Similar funds

DAM
Delta Asset Management Memphis, Tennessee $1.1B AUM 14.89% 1-Year Est. Return
MAM
Mark Asset Management New York $1.1B AUM 43.79% 1-Year Est. Return
LCM
Legato Capital Management San Francisco, California $1.1B AUM 61.65% 1-Year Est. Return
DAM
DLD Asset Management New York $1.1B AUM 4.68% 1-Year Est. Return
KCM
Khrom Capital Management Miami Beach, Florida $1.09B AUM 14.82% 1-Year Est. Return
CF
Corebridge Financial Houston, Texas $1.09B AUM 1.85% 1-Year Est. Return
MIA
MMBG Investment Advisors Miami, Florida $1.09B AUM 30.96% 1-Year Est. Return
YL
YCG LLC Austin, Texas $1.1B AUM 4.87% 1-Year Est. Return

PFM Health Sciences's Q2 2024 Portfolio in Review

As of Q2 2024, PFM Health Sciences held 96 positions worth $2.02B, down 5% from $2.13B the previous quarter. Its ten largest holdings account for 46% of the portfolio.

PFM Health Sciences's Q2 2024 filing shows 10 new, 23 increased, 12 reduced and 18 closed positions. Its largest new stake was Amgen: 81,034 shares worth $25.3M. The largest sale was Legend Biotech, an estimated $41.2M.

By sector, the portfolio is most concentrated in Healthcare at 89% of assets, down from 90% a quarter earlier.

  • PFM Health Sciences's largest Q2 2024 buy was Amgen: 81,034 shares worth $25.3M.
  • PFM Health Sciences added most to UnitedHealth in Q2 2024, an estimated $24.5M increase.
  • PFM Health Sciences's biggest Q2 2024 reduction was Becton Dickinson, cutting an estimated $9.46M.
  • PFM Health Sciences fully exited Legend Biotech in Q2 2024, selling an estimated $41.2M.
  • PFM Health Sciences's ten largest holdings make up 46% of its $2.02B portfolio in Q2 2024.
  • PFM Health Sciences opened 10 new positions and closed 18 in Q2 2024.
  • PFM Health Sciences's portfolio value fell 5% quarter-over-quarter to $2.02B.

Based on PFM Health Sciences's 13F filing for Q2 2024, filed 14 Aug 2024.